Further assessment of PPC risk after RRBSO in BRCA1/2 PV carriers where STIC lesions were identified may justify some sort of an intervention, such as staging CT scan to exclude metastatic disease or even a course of PARP inhibitor treatment if substantial rates continue to be reported.18 Here, BRCA1 is linked to metastatic neoplasm.